Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio +7
Journal of Clinical Oncology
Medicine
PURPOSE: Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage...
Internet, mail, and mixed-mode surveys: The tailored design method *
Angela P. Wetzel
Journal of Continuing Education in the Health Professions